Patients receiving low dose steroid at increased risk of cardiovascular disease

8 December 2020


08 December 2020

Glucocorticoids are steroids widely prescribed to treat a range of immune-mediated inflammatory diseases. While high doses of steroids are known to increase the risk of cardiovascular disease, the impact of lower doses is unknown. A study published in PLOS Medcine by Mar Pujades-Rodriguez at Leeds University and colleagu

es suggests that even low doses of glucocorticoid may increase the risk of cardiovascular diseases.

To quantify glucocorticoid dose-dependent cardiovascular risk, researchers analyzed medical records of 87,794 patients diagnosed with 6 different immune-mediate inflammatory diseases receiving care from 389 United Kingdom primary care clinics in 1998-2017. The researchers found that for patients using less than 5 milligrams prednisolone per day, the absolute risk of cardiovascular disease nearly doubled compared to patients not us

ing glucocorticoids (Hazard Ratio = 1.74; 95% confidence interval 1.64–1.84). Increased dose-dependent risk ratios were found across all CVDs measured, including atrial fibrillation, heart failure, acute myocardial infarction, peripheral arterial disease, cerebrovascular disease, and abdominal aortic aneurysm.

Previously, it was believed that tak

ing 5 mg of glucocorticoid over the long-term was safe, but the study suggests that even patients taking low doses have double the risk of developing cardiovascular disease. These findings suggest patients needing long-term steroid treatment should be prescribed the lowest effective dose and have a personalized cardiovascular risk prevention plan that accounts for past and current steroid use. Although the study was limited by the lack of available hospital data on prescription and drug adherence and this may have reduced the size of dose-response estimates, the authors believe that the large sample size from an unselected population contributes to greater generalizability of the results.

According to the authors, “Our findings highlight the importance of implementing and evaluating targeted intensive cardiovascular risk factor modification interventions; promptly and regularly monitor patient cardiovascular risk, beyond diagnosis of inflammatory arthropathies and systemic lupus erythematosus, even when prescribing low prednisolone-equivalent doses”.

Read the full peer reviewed publication at PloS Medicine.

Related Themes

Related Team Members

Professor Ann Morgan

Associate Director of Translational Research



Related News